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Abstract
Background: Lymph node dissection has proven prognostic benefits for patients with ovarian or
uterine carcinoma; however, one of the complications associated with this procedure is
lymphedema. We aimed to identify the factors that are associated with the occurrence of
lymphedema after lymph node dissection for the treatment of ovarian or uterine carcinoma.
Methods: A total of 694 patients with histologically confirmed ovarian (135 patients) or uterine
cancer (258 with cervical cancer, 301 with endometrial cancer) who underwent lymph node
dissection were studied retrospectively. Logistic regression analyses were used to identify the risk
factors associated with occurrence of lymphedema.
Results: Among ovarian and uterine cancer patients who underwent pelvic lymph node dissection,
post-operative radiotherapy (odds ratio: 1.79; 95% confidence interval: 1.20–2.67; p = 0.006) was
statistically significantly associated with occurrence of lymphedema.
Conclusion:  There was no relationship between any surgical procedure and occurrence of
lymphedema among patients undergoing pelvic lymphadenectomy. Our findings are supported by a
sound biological rationale because they suggest that limb lymphedema is caused by pelvic lymph
node dissection.
Background
After breast cancer, ovarian and uterine carcinomas are the
next most-common gynecological malignancies in Japan
[1]. Owing to the recent development of effective chemo-
therapeutic agents and regimens, some cases of ovarian
cancer are now curable with a combination of surgery and
chemotherapy, and the survival of patients has continued
to improve [2]. For early-stage ovarian cancer, the stand-
ard therapy is complete surgical staging followed by
abdominal hysterectomy and bilateral salpingo-
oophorectomy with omentectomy and selective lym-
phadenectomy. Uterine cancer is also potentially curable
using the following therapeutic approaches: (i) radiation,
(ii) surgery, and (iii) chemotherapy [1]. As more effective
modes of treatment, such as extended surgical removal
and lymph node dissection are implemented, many
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patients with ovarian or uterine carcinoma have been
cured and survivorship has continued to increase [3].
However, an important but sometimes overlooked sequel
to these treatments is lymphedema of the lower limbs [4].
This is a chronic, incurable condition, the effects of which
include limb swelling and feelings of heaviness, tightness,
and pain [5]. Lymphedema can take a psychological toll,
with patients experiencing symptoms such as anxiety,
depression, and adjustment problems [6]. Consequently,
lymphedema can affect the patients' vocational, domestic,
social, and sexual lives and adversely affect their quality of
life [7]. Hence, prevention of lymphedema has become an
important issue in the care of patients who undergo lym-
phadenectomy.
In previous studies, risk factors for the incidence of
lymphedema have been identified, including the removal
of pelvic lymph nodes [8,9] subsequent to the diagnosis
of malignancy, which may obstruct the flow of lymphatic
fluid from the lower limbs [10]. Also, a recent study found
that patients who had 10 or more regional lymph nodes
removed during the initial surgery appeared to be at a
higher risk for developing new symptomatic limb lymph-
edema [11]. It is unclear which surgical procedures elevate
the risk of lower limb lymphedema (LLL) after lymph
node dissection for gynecological malignancies. We con-
ducted a retrospective study to identify the risk factors that
were associated with occurrence of LLL after lymph node
dissection for the treatment of ovarian or uterine carci-
noma.
Methods
A total of 694 patients with histologically proven uterine
(258 patients with cervical cancer and 301 with endome-
trial cancer) or ovarian (135 patients) carcinoma treated
with lymph node dissection between January 1997 and
December 1998 were enrolled consecutively at 10 Japa-
nese hospitals (The Jikei University School of Medicine
Hospital, Sapporo Medical University Hospital, Niigata
Cancer Center Hospital, Hyogo Medical Center for Adults,
Aichi Cancer Center, Toyama Prefectural Central Hospi-
tal, National Kure Medical Center, Shikoku Cancer
Center, Nagasaki University, Shinshu University Hospi-
tal). Lymphadenectomy was defined as surgery to remove
more than twenty lymph nodes. The protocol of this study
was approved by the ethics committee at each institution.
Informed consent was obtained from each of the patients
during their visit, after an explanation of the study and its
methods, including collection of data from their past
medical records.
Patients who had another active cancer at the time of sur-
gery and/or patients who had received treatment for dis-
tant metastases were excluded. Also, we excluded patients
with LLL at baseline.
A retrospective review was conducted on the medical
records of all the participating women. Data collected
included age, pre-treatment FIGO clinical stage (Interna-
tional Federation of Gynecology and Obstetrics 1995),
metastatic status, number of pregnancies and deliveries,
post-surgical histopathological classification (Interna-
tional Union Against Cancer, TNM Classification of
Malignant Tumours), and pelvic tumor status.
Treatment-related information collected included the date
of operation, operative procedures undergone, whether
pelvic and para-aortic lymph node dissection or both were
carried out, and which preoperative and postoperative
adjuvant therapies were administered, including chemo-
therapy and radiation therapy. We defined preoperative
and postoperative adjuvant therapies as those performed
within six months before or after the resective operation,
respectively.
We identified patients with lymphedema through their
medical records or subjective judgment by the patients
regarding swelling and heaviness of the legs. LLL was iden-
tified via a thorough review of all available records. The
study focused only on 'symptomatic' limb lymphedema.
It is very likely that some patients in this study had mini-
mal or mild limb lymphedema that would have been
detected only by prospective serial limb circumference or
volume measurements, which were not undertaken in this
retrospective study. The women described symptomatic
and persistent swelling in one or both lower limbs, which
developed following treatment for her cancer and that
could not be attributed to any other cause.
The primary endpoint of this study was the occurrence of
LLL. The incidence of lymphedema was tested using
Fisher's exact test according to cancer type, in relation to
surgical factors that might influence the onset of lymphe-
dema (retroperitoneal approach (opening or closing),
omentectomy, enterectomy, hysterectomy, salpingo-
oophorectomy, and lymph node dissection), as well as
other factors, including patient characteristics and a his-
tory of chemotherapy and/or radiotherapy. Logistic
regression was used to assess the relationship between
lymphedema and radiotherapy. SAS ver. 8.2 (SAS Insti-
tute, Cary, NC, USA) was used for the analysis. All
reported p-values relate to two-tailed statistical tests.
Results
Patients' clinical characteristics and treatments received
are summarized in Table 1. Almost all patients (98%)
underwent pelvic lymph node dissection. More than half
the patients underwent bilateral salpingo-oophorectomy.BMC Cancer 2009, 9:47 http://www.biomedcentral.com/1471-2407/9/47
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Twenty-eight ovarian cancer patients (20.7%), 78 cervical
cancer patients (30.2%) and 83 endometrial cancer
patients (27.6%) developed lymphedema, with no statis-
tically significant difference between the percentages in
the three groups (p = 0.130). The median times from
operation to occurrence of LLL were 4.6 months (range:
0.1–40.2 months) for ovarian cancer patients, 4.2 months
(range: 0.1–50.7 months) for cervical cancer patients, and
6.8 months (range: 0.1–45.3 months) for endometrial
cancer patients (p = 0.258).
The results of the univariate analyses for patients who
underwent pelvic lymph node dissection (n = 680) are
shown in Table 2. Post-operative radiotherapy (odds ratio
(OR): 1.79; 95% confidence interval (CI): 1.20–2.68; p =
0.006) was significantly associated with the occurrence of
LLL. Among patients undergoing pelvic lymphadenec-
tomy there was no correlation between any surgical proce-
dure and LLL. Para-aortic lymph node dissection (OR:
1.34; 95% CI: 0.91–19.6; p = 0.158) was not a risk factor
for LLL.
Table 1: Summary of the clinical characteristics of patients involved in this study (N = 694; all female)
Clinical characteristics Ovarian cancer Cervical cancer Endometrial cancer
Total no. patients 135 258 301
Age (years) Median 51 49 57
Range 15–79 23–80 19–80
FIGO stage (N; %) I 64 (47.4) 171 (66.3) 196 (65.1)
II 11 (8.2) 76 (29.5) 27 (9.0)
III-IV 60 (44.4) 11 (4.3) 75 (24.9)
Unknown - - - - 3 (1.0)
Surgical procedure (N; %) Retroperitoneal
Closing 80 (59.3) 184 (71.3) 205 (68.1)
Opening 32 (23.7) 16 (6.2) 33 (11.0)
- 23 (17.0) 58 (22.5) 63 (20.9)
Omentectomy
+ 87 (64.4) 0 (0.0) 25 (8.3)
- 48 (35.6) 258 (100.0) 276 (91.7)
Enterectomy
+ 9 (6.7) 1 (0.4) 0 (0.0)
- 126 (93.3) 257 (99.6) 301 (100.0)
Salpingo-oophorectomy
Unilateral 18 (13.3) 34 (13.2) 38 (12.6)
Bilateral 108 (80.0) 133 (51.6) 203 (67.4)
- 9 (6.7) 91 (35.3) 60 (19.9)
Pelvic lymph node dissection
+ 133 (98.5) 252 (97.7) 295 (98.0)
- 2 (1.5) 6 (2.3) 6 (2.0)
Para-aortic lymph node dissection
+ 71 (52.6) 28 (10.9) 66 (21.9)
- 64 (47.4) 230 (89.1) 235 (78.1)
Hysterectomy
Total 93 (68.9) 6 (2.3) 112 (37.2)
Modified radical 31 (23.0) 18 (7.0) 150 (49.8)
Radical 3 (2.2) 230 (89.1) 39 (13.0)
- 8 (5.9) 4 (1.6) 0 (0.0)
Chemotherapy (N; %) Neo-adjuvant chemotherapy
+ 9 (6.7) 20 (7.8) 6 (2.0)
- 126 (93.3) 238 (92.2) 295 (98.0)
Adjuvant chemotherapy
+ 111 (82.2) 62 (24.0) 119 (39.5)
- 24 (17.8) 196 (76.0) 182 (60.5)
Radiotherapy (N; %) Pre-operative radiation
+ 0 (0.0) 6 (2.3) 0 (0.0)
- 135 (100.0) 252 (97.7) 301 (100.0)
Post-operative radiation
+ 1 (0.7) 107 (41.5) 29 (9.6)
- 134 (99.3) 151 (58.5) 272 (90.4)BMC Cancer 2009, 9:47 http://www.biomedcentral.com/1471-2407/9/47
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Given that different types of cancer require different hys-
terectomy procedures, we reclassified the patients into
those with ovarian or endometrial cancer, who underwent
less radical hysterectomy, and those with cervical cancer,
who underwent more radical hysterectomy. There was no
statistically significant risk factor identified for patients
with ovarian or endometrial cancer, but for cervical cancer
patients, post-operative radiotherapy was a statistically
significant factor for the occurrence of lymphedema (OR:
1.77; 95% CI: 1.03–3.06; p = 0.049).
Discussion
Lymphedema is generally caused by an obstruction or
interruption of the lymphatic system, generally in proxi-
mal limb segments at lymph nodes, due to infection,
malignancy, or scar tissue [12]. The pelvic and inguinal
groups of nodes in the lower limbs are the primary sites of
obstruction [13]. When the lymphatic system has been
damaged by surgery, its capacity to absorb excess water
and cells from the interstitial space is reduced. If the trans-
port capacity of the lymphatic system is so reduced that it
cannot manage this increase in lymphatic load, an insuf-
ficiency of the lymphatic system will occur [6].
In this study, we found that patients with ovarian cancer
had a lower incidence of LLL than did patients with uter-
ine cancer. In a previous study, similar results were found
Table 2: Relationship between factors and lymphedema in ovarian and uterine cancer patients who underwent pelvic lymph node 
dissection (univariate analysis; N = 680)
Factor Category N No. cases of lymphedema Lymphedema incidence (%) p value*
Cancer type Ovarian 133 28 21.1
Cervical 252 75 29.8
Endometrial 295 82 27.8 0.175
Age < 53 years 342 93 27.2
≥ 53 years 338 92 27.2 1.000
Retroperitoneal approach** Closing 457 131 28.7
Opening 79 24 30.4 0.789
Omentectomy - 569 160 28.1
+ 111 25 22.5 0.245
Enterectomy - 670 181 27.0
+ 10 4 40.0 0.473
Salpingo-oophorectomy - 160 45 28.3
Unilateral 87 25 28.7
Bilateral 433 115 26.6 0.873
Hysterectomy - 12 4 33.3
Total 206 53 25.7
Modified radical 196 51 26.0
Radical 266 77 29.0 0.767
Neo-adjuvant chemotherapy - 645 173 26.8
+3 5 1 2 3 4 . 3 0 . 3 3 4
Adjuvant chemotherapy - 393 111 28.2
+ 287 74 25.8 0.487
Post-operative radiation - 548 136 24.8
+ 132 49 37.1 0.006
Para-aortic lymph node dissection - 516 133 25.8
+ 164 52 31.7 0.158
Total 680 185 27.2
* Fisher's exact test
** Except for 144 patients for whom this information was unknown.BMC Cancer 2009, 9:47 http://www.biomedcentral.com/1471-2407/9/47
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with respect to the incidence of LLL (ovarian cancer: 7.1%;
uterine cancer 17.7%; cervical cancer: 17.5%) [14].
Most patients in the present study underwent pelvic
lymph node dissection. We found that for ovarian and
uterine cancer patients who underwent pelvic lymph node
dissection, post-operative radiotherapy was significantly
associated with the occurrence of LLL. Post-operative radi-
otherapy was found to be an independent risk factor for
LLL in the present study, confirming the results of previ-
ous studies [3,15-17]. Of all patients with ovarian cancer
in the present study, only one patient received post-oper-
ative radiotherapy, compared with 136 of the uterine can-
cer patients. The lower incidence of LLL in patients with
ovarian cancer might be due to these patients not gener-
ally receiving radiation therapy after surgery.
In this study, we found that for patients with ovarian and
uterine cancer, para-aortic lymph node dissection is not a
significant risk factor for LLL. This finding has a clear bio-
logical rationale because it suggests that LLL is caused by
pelvic lymph node dissection.
The study design used in the present study had some lim-
itations. Firstly, occurrence of LLL was assessed in a sub-
jective way, and there was no measurement of the severity
of the symptoms, nor of the extent of the associated func-
tional impairment. Secondly, we collected no informa-
tion on the extent of lymph node disease, nor the number
of lymph nodes dissected, although previous studies have
suggested that the number of lymph nodes surgically
removed and the extent of metastatic disease in the lymph
nodes are risk factors for lymphedema [10]. Given that we
did not collect these data, the relationship between the
incidence of LLL and these factors could not be clarified.
However, all the institutions that participated in this study
specialized in the surgical treatment of ovarian and uter-
ine cancer, and within these institutions twenty or more
pelvic and para-aortic lymph nodes are usually removed
at operation by gynecological oncologists. Therefore, the
patients included in our study can be regarded as having
undergone maximum lymph node dissection.
Although at this stage there are no appropriate alternative
surgical procedures available to decrease the risk of LLL,
our findings have clinical implications with respect to
when pelvic lymph node dissection should or should not
be performed.
It is important to identify patients at risk of lymphedema
early and to begin preventive monitoring and instruction
in self-care as soon as possible. The role of nursing in the
acute and community care of women at risk of developing
LLL includes ensuring that women being discharged are
aware of the early signs and symptoms of lower limb
lymphedema and how to access qualified, specialized
therapists so that effective early management can be initi-
ated [18]. The following parameters are reportedly helpful
in the early detection of lymphedema: the ratio of actual
to ideal weight, extremity measurements, ability to per-
form activities of daily living, a history of contributing fac-
tors and concurrent medical illnesses (as identified
previously for breast cancer patients) [18,19].
Conclusion
Post-operative radiation was found to be a risk factor for
occurrence of LLL among uterine cancer patients who
underwent pelvic lymph node dissection. However, there
was no association between any surgical procedure and
occurrence of lymphedema among patients undergoing
pelvic lymphadenectomy. Our findings have a strong
underlying biological rationale because they suggest that
limb lymphedema is caused by pelvic lymph node dissec-
tion.
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